Implementing a Sodium-Glucose Cotransporter 2 Inhibitor Module With a Software Tool (Future Health Today): Qualitative Study
BackgroundPrimary care plays a key role in the management of type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been demonstrated to reduce hospitalization and cardiac and renal complications. Tools that optimize management, including appropriate prescrib...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2024-03-01
|
| Series: | JMIR Formative Research |
| Online Access: | https://formative.jmir.org/2024/1/e50737 |
| _version_ | 1797263354510704640 |
|---|---|
| author | Matthew Suen Jo-Anne Manski-Nankervis Caroline McBride Natalie Lumsden Barbara Hunter |
| author_facet | Matthew Suen Jo-Anne Manski-Nankervis Caroline McBride Natalie Lumsden Barbara Hunter |
| author_sort | Matthew Suen |
| collection | DOAJ |
| description |
BackgroundPrimary care plays a key role in the management of type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been demonstrated to reduce hospitalization and cardiac and renal complications. Tools that optimize management, including appropriate prescribing, are a priority for treating chronic diseases. Future Health Today (FHT) is software that facilitates clinical decision support and quality improvement. FHT applies algorithms to data stored in electronic medical records in general practice to identify patients who are at risk of a chronic disease or who have a chronic disease that may benefit from intensification of management. The platform continues to evolve because of rigorous evaluation, continuous improvement, and expansion of the conditions hosted on the platform. FHT currently displays recommendations for the identification and management of chronic kidney disease, cardiovascular disease, type 2 diabetes, and cancer risk. A new module will be introduced to FHT focusing on SGLT2 inhibitors in patients with type 2 diabetes who have chronic kidney diseases, cardiovascular diseases, or risk factors for cardiovascular disease.
ObjectiveThe study aims to explore the barriers and enablers to the implementation of an SGLT2 inhibitor module within the Future Health Today software.
MethodsClinic staff were recruited to participate in interviews on their experience in their use of a tool to improve prescribing behavior for SGLT2 inhibitors. Thematic analysis was guided by Clinical Performance Feedback Intervention Theory.
ResultsIn total, 16 interviews were completed. Identified enablers of use included workflow alignment, clinical appropriateness, and active delivery of the module. Key barriers to use were competing priorities, staff engagement, and knowledge of the clinical topic.
ConclusionsThere is a recognized benefit to the use of a clinical decision support tool to support type 2 diabetes management, but barriers were identified that impeded the usability and actionability of the module. Successful and effective implementation of this tool could support the optimization of patient management of type 2 diabetes in primary care. |
| first_indexed | 2024-04-25T00:11:40Z |
| format | Article |
| id | doaj.art-cd4c6e4e357b4726bcbca6aebc60f43d |
| institution | Directory Open Access Journal |
| issn | 2561-326X |
| language | English |
| last_indexed | 2024-04-25T00:11:40Z |
| publishDate | 2024-03-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | JMIR Formative Research |
| spelling | doaj.art-cd4c6e4e357b4726bcbca6aebc60f43d2024-03-13T13:00:34ZengJMIR PublicationsJMIR Formative Research2561-326X2024-03-018e5073710.2196/50737Implementing a Sodium-Glucose Cotransporter 2 Inhibitor Module With a Software Tool (Future Health Today): Qualitative StudyMatthew Suenhttps://orcid.org/0000-0003-2899-2446Jo-Anne Manski-Nankervishttps://orcid.org/0000-0003-2153-3482Caroline McBridehttps://orcid.org/0000-0002-8273-3894Natalie Lumsdenhttps://orcid.org/0000-0002-7471-2487Barbara Hunterhttps://orcid.org/0000-0002-1268-3166 BackgroundPrimary care plays a key role in the management of type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been demonstrated to reduce hospitalization and cardiac and renal complications. Tools that optimize management, including appropriate prescribing, are a priority for treating chronic diseases. Future Health Today (FHT) is software that facilitates clinical decision support and quality improvement. FHT applies algorithms to data stored in electronic medical records in general practice to identify patients who are at risk of a chronic disease or who have a chronic disease that may benefit from intensification of management. The platform continues to evolve because of rigorous evaluation, continuous improvement, and expansion of the conditions hosted on the platform. FHT currently displays recommendations for the identification and management of chronic kidney disease, cardiovascular disease, type 2 diabetes, and cancer risk. A new module will be introduced to FHT focusing on SGLT2 inhibitors in patients with type 2 diabetes who have chronic kidney diseases, cardiovascular diseases, or risk factors for cardiovascular disease. ObjectiveThe study aims to explore the barriers and enablers to the implementation of an SGLT2 inhibitor module within the Future Health Today software. MethodsClinic staff were recruited to participate in interviews on their experience in their use of a tool to improve prescribing behavior for SGLT2 inhibitors. Thematic analysis was guided by Clinical Performance Feedback Intervention Theory. ResultsIn total, 16 interviews were completed. Identified enablers of use included workflow alignment, clinical appropriateness, and active delivery of the module. Key barriers to use were competing priorities, staff engagement, and knowledge of the clinical topic. ConclusionsThere is a recognized benefit to the use of a clinical decision support tool to support type 2 diabetes management, but barriers were identified that impeded the usability and actionability of the module. Successful and effective implementation of this tool could support the optimization of patient management of type 2 diabetes in primary care.https://formative.jmir.org/2024/1/e50737 |
| spellingShingle | Matthew Suen Jo-Anne Manski-Nankervis Caroline McBride Natalie Lumsden Barbara Hunter Implementing a Sodium-Glucose Cotransporter 2 Inhibitor Module With a Software Tool (Future Health Today): Qualitative Study JMIR Formative Research |
| title | Implementing a Sodium-Glucose Cotransporter 2 Inhibitor Module With a Software Tool (Future Health Today): Qualitative Study |
| title_full | Implementing a Sodium-Glucose Cotransporter 2 Inhibitor Module With a Software Tool (Future Health Today): Qualitative Study |
| title_fullStr | Implementing a Sodium-Glucose Cotransporter 2 Inhibitor Module With a Software Tool (Future Health Today): Qualitative Study |
| title_full_unstemmed | Implementing a Sodium-Glucose Cotransporter 2 Inhibitor Module With a Software Tool (Future Health Today): Qualitative Study |
| title_short | Implementing a Sodium-Glucose Cotransporter 2 Inhibitor Module With a Software Tool (Future Health Today): Qualitative Study |
| title_sort | implementing a sodium glucose cotransporter 2 inhibitor module with a software tool future health today qualitative study |
| url | https://formative.jmir.org/2024/1/e50737 |
| work_keys_str_mv | AT matthewsuen implementingasodiumglucosecotransporter2inhibitormodulewithasoftwaretoolfuturehealthtodayqualitativestudy AT joannemanskinankervis implementingasodiumglucosecotransporter2inhibitormodulewithasoftwaretoolfuturehealthtodayqualitativestudy AT carolinemcbride implementingasodiumglucosecotransporter2inhibitormodulewithasoftwaretoolfuturehealthtodayqualitativestudy AT natalielumsden implementingasodiumglucosecotransporter2inhibitormodulewithasoftwaretoolfuturehealthtodayqualitativestudy AT barbarahunter implementingasodiumglucosecotransporter2inhibitormodulewithasoftwaretoolfuturehealthtodayqualitativestudy |